Debra L. Ellies, Ph.D. - CEO, President & Chairman of the Board of Directors

In 2006 Dr. Ellies founded OsteoGeneX Inc (OGX), and has worked to develop the unique business strategy for OsteoGeneX Inc. Prior to launching OGX, Dr Ellies was at the Stowers Medical Research Institute in Kansas City, MO. While at the Stowers Institute, Dr. Ellies was the key scientist in the epochal discovery of Sclerostin as a modulator of the WNT pathway. Dr. Ellies was also part of the scientific team which discovered that the CCN family also functioned via WNT signaling. Furthermore, Ellies & Krumlauf were the first to report that Sclerostin blocking antibodies function by blocking Sclerostin action on the WNT pathway. Prior to her work at Stowers, Dr. Ellies conducted basic research on the developmental significance of programmed cell death, the role in Wnt signaling and managed a laboratory at Ottawa Civic Hospital in Ottawa, Canada. In addition to her remarkable successes in the laboratory, Dr. Ellies co-founded the Brian Ellies Esophageal Cancer Prevention Fund, which works to educate the public and promote awareness of esophageal cancer prevention. Dr. Ellies is the author of several international key scientific manuscripts in the area of signal transduction, and of a number of patents, and a reviewer for Center for Scientific Reviewer at NIH. She received her Ph.D. from Guy’s Hospital London, UK, under the supervision of Prof. Andrew Lumsden, FRS; M.Sc. from University Ottawa, LOEB Research Institute, Canada.

William S. Rosenberg, M.D. - Chief Medical Officer & Chairman of the Scientific Advisory Board

Dr. Rosenberg joined OsteoGeneX in March 2007 as Chief Medical Officer. Dr. William S. Rosenberg, MD, is an innovator in both his practice of medicine and in the development of new technologies and devices in life sciences. Dr. Rosenberg specializes in complex spinal surgery as a neurosurgeon with Midwest Neurosurgery Associates in Kansas City. Prior to joining his current group, he was Director of the Neurospinal Disorders Program at University of California, San Francisco and Co-Founder of the Spine Biomechanics Laboratory at University of California, Berkeley. Dr. Rosenberg received his medical degree from Harvard Medical School and trained in neurosurgery at Massachusetts General Hospital in Boston. In addition to his medical practice, Dr. Rosenberg has served as a consultant for a number of medical device companies in various stages of development and holds several patents for surgical devices and techniques.

Christine has over 20 years of experience in academic, medical and Fortune 10 pharmaceutical industries. Most recently she was Executive Director of Licensing & Development at Pfizer, where she spent 12 years in their licensing group focusing on in-licensing in several therapeutic areas including the neurosciences, infectious diseases, dermatology, and ophthalmology areas. She also was responsible for external searches for new opportunities and led multidisciplinary teams conducting technical evaluation, due diligence, and financial valuation for licensing and co-promotion deals with biotech and big pharma firms. While at Pfizer, she also held senior positions in their US and international marketing and medical groups. Christine began her career as Assistant Professor of Pharmacology teaching undergraduate and graduate level courses in clinical pharmacy at the University of Texas. From there she became Director of Clinical Research at Mt. Sinai Medical Center in New York, before joining Pfizer in 1989. Christine earned her Doctorate in Clinical Pharmacy from the University of Texas, and a Masters in Business Administration from St. Joseph’s University.

During a three decade career, Dr. MacDonald has brought hundreds of new molecular entities forward from discovery into development, over thirty of which have become globally registered, major drugs, including Vasotec®, Zocor®, Primaxin®, Clinoril®, Pepcid®, Fosamax®, Clarinex®, Nasonex®, and Vitorin®, among others. Until his retirement in 2008, he was Executive Vice President of Preclinical Development for Schering-Plough Research Institute (SPRI), the pharmaceutical development arm of Schering Corporation. Joining SPRI in 1994, over the next 14 years Dr. MacDonald played a leading role in building one of the most capable drug development organizations in the world. In addition to his line responsibility for Drug Safety and Metabolism, as co-chairman of SPRI’s Early Development Committee he directed the activities surrounding the movement of drug candidates from discovery research into and through the development process. From 1977 until 1994, Dr. MacDonald held positions of increasing responsibility at Merck, including Executive Director of Toxicology. Dr. MacDonald received his B.A. Biology and Chemistry DePauw University, Indiana and his Ph.D. in toxicology in 1975 from the University of Cincinnati. He joined Merck after completing a post-doctoral fellowship at Vanderbilt University. Dr. MacDonald became a diplomat of the American Board of Toxicology in 1980.

Michael Beckloff is President of Beckloff Associates, Inc., Overland Park, Kansas. Founded in 1976, Beckloff Associates, Inc. (BAI), a wholly-owned subsidiary of Cardinal Health, provides a wide range of consulting services required to obtain marketing approval for drugs, biologics and medical devices for the U.S., Canadian and European markets. They have successfully supported worldwide drug development across a broad range of therapeutic categories and have worked with virtually all types of product formulations.

Sam Campbell is President and CEO of CritiTech, Inc. and has over twenty years of experience in managing early stage life science and technology companies. He currently is also the President of Campbell-Becker, Inc., a company that specializes in assisting early stage companies properly organize and finance their growth. He and his associates have provided start-up capital to numerous life science companies and worked with them to develop their company strategy and its implementation.

Bruce W. Jenett is Partner and Co-Chair of the Global Life Sciences Sector at DLA Piper in East Palo Alto, California. Mr. Jenett is a renowned life science lawyer who brings over 25 years of industry experience focused on the representation of domestic and international business and finance clients in the life sciences industry. He received his J.D. from Georgetown University Law Center and a B.A. from Princeton. Mr Jenett is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both start-ups and large multinational corporations. Among his many accomplishments, Mr. Jenett handled one of the largest ag-bio partnering deals in history, as well as one of the largest partnering deals ever done by an Irish venture capital-backed biotechnology company with a major pharmaceutical company. A frequent speaker on corporate and finance issues to both business and attorney audiences, Mr. Jenett is also a member of the Bioethics Committee of BIO, and of the BayBio Board of Directors, and he is a member of, and Co-Chair of the Strategic Planning Committee of, San Francisco Mayor Gavin Newsom’s Biotech Advisory Council. Chambers & Partners: America’s Leading Lawyers for Business consistently names him one of the leading business lawyers in the United States.

Enrico Picozza is a Venture Partner at HLM Venture Partners and a serial entrepreneur. He has founded or served as a member of the startup team for several companies that address markets such as diagnostics and regenerative medicine. In 2000 Enrico was a Founder, COO/CTO and board member for HTS Biosystems, a systems development company. Under Enrico's stewardship HTS successfully developed and launched cutting edge products, which are now sold by GE Health Care. Preceding HTS Enrico's entrepreneurial career started at Perkin-Elmer immediately after graduation from the University of Connecticut. Enrico was the first member to join the newly formed Biotechnology group that was responsible for developing and commercialization of the PCR technology. After 7 years and 120 million in sales this team became the catalyst for what is today Applera. His involvement in the success of PCR was later recognized by the Smithsonian. Today that product has a market value of > 5 billion dollars. Enrico's experience includes international business, IP management, research & development, sales and marketing. Market experience includes MDX, forensics, drug discovery, medical devices, proteomics and emerging markets. Presently Enrico is interim CEO to CELTHERA a regenerative medicine company, he also serves as advisor to multiple other young companies, established companies, venture firms and academic organizations.

Scott Weir is the Director of the Office of Therapeutics, Discovery and Development (OTDD), Kansas University. Dr. Weir’s role is to identify, organize and implement drug discovery and early drug development. Dr. Weir has over 20 years of professional experience in the field of drug discovery and development. At Marion Laboratories, Inc. he was directly involved in the successful registration of several drug products. Furthermore, at Quintiles, Dr. Weir managed an early drug development division which included pharmacology, toxicology, drug metabolism and harmacokinetics, bioanalytical, and clinical pharmacology services.